Oncology Xagena
Ipilimumab ( Yervoy ) is a fully human monoclonal antibody that binds cytotoxic T-lymphocyte antigen 4 to enhance antitumour immunity. A study has assessed the use of Ipilimumab after radiotherapy i ...
The U.S. Food and Drug Administration ( FDA ) has approved Keytruda ( Pembrolizumab ) at a dose of 2 mg/kg every three weeks for the treatment of patients with unresectable or metastatic melanoma and ...
The results from CheckMate -037, a phase 3 randomized, controlled open-label study of Nivolumab ( Opdivo ), an investigational PD-1 immune checkpoint inhibitor, versus investigator’s choice chemothera ...
Data on the investigational use of Pembrolizumab ( Keytruda ), an anti-PD-1 agent, in PD-L1 positive, advanced gastric cancer were presented during the ESMO ( European Society for Medical Oncology ) 2 ...
Data on the investigational use of Pembrolizumab ( Keytruda ), an anti-PD-1 agent, in PD-L1 positive, advanced urothelial cancer ( also known as bladder cancer ) presented at ESMO ( European Society f ...
The anti-programmed-death-receptor-1 ( PD-1 ) antibody Pembrolizumab ( Keytruda ) has shown potent antitumour activity at different doses and schedules in patients with melanoma. Researchers have co ...
Findings investigating the use of Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, in multiple, difficult-to-treat cancers, including advanced small cell lung cancer ( SCLC ), esophageal cancer and o ...
A review, titled Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential, from researchers at The University of Texas MD Anderson Cancer Center published i ...
A phase I/II study in patients with metastatic castration-resistant prostate cancer ( mCRPC ) explored Ipilimumab ( Yervoy ) as monotherapy and in combination with radiotherapy, based on the preclinic ...
Cancer radiotherapy ( RT ) may induce what is referred to as the abscopal effect, a regression of non-irradiated metastatic lesions distant from the primary tumor site directly subject to irradiation. ...
Immune checkpoint blockade may play a role in the treatment of metastatic urothelial cancer ( mUC ). However, the role of CTLA4 blockade, the impact of chemotherapy on immune cell populations, and the ...
In a phase III trial, Ipilimumab ( Yervoy ) significantly improved survival versus a vaccine control in pretreated patients with metastatic melanoma. Researchers have characterized outcomes of those ...
Patients with melanoma brain metastases have a poor prognosis and historically have been excluded from clinical trials. The Expanded Access Program ( EAP ) provided an opportunity to evaluate the f ...
Elderly patients with metastatic melanoma have different disease characteristics and a poorer prognosis than younger patients. Data from clinical trials and expanded access programmes ( EAPs ) sugge ...
The advent of new immunotherapies for the treatment of metastatic melanoma has resulted in various novel combination strategies. Because of their distinct modes of action, different immunotherapies ha ...
